STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (KL-188)	ADINTREVIMAB
PRONUNCIATION	a” din trev’ i mab
THERAPEUTIC CLAIM	The prevention of SARS-CoV-2 infection and the subsequent disease, COVID-19

CHEMICAL NAMES

1. Immunoglobulin G1 [435-leucine,441-alanine], anti-(severe acute respiratory syndrome coronavirus 2 spike glycoprotein) (human monoclonal ADG20 γ1-chain), disulfide with human monoclonal ADG20 λ-chain, dimer (Source: CAS)

2. Immunoglobulin G1-lambda2, anti-[severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S) glycoprotein, receptor binding domain (RBD)], *Homo sapiens* monoclonal antibody; gamma1 heavy chain *Homo sapiens* (1-454) [VH (*Homo sapiens* IGHV3-21*01 (88.8%) -(IGHD) -IGHJ4*01 (92.9%), CDR-IMGT [8.8.17] (26-33.51-58.97-113)) (1-124) -*Homo sapiens* IGHG1*03, G1m3, nG1m1, G1v24 CH3 L107, S114 (CH1 R120 (221) (125-222), hinge 1-15 (223-237), CH2 (238-347), CH3 E12 (363), M14 (365), M107>L (435), N114>A (441) (348-452), CHS (453-454)) (125-453)], (227-217')-disulfide with lambda2 light chain *Homo sapiens* (1'-218') [V-LAMBDA (*Homo sapiens* IGLV1-40*01 (95.9%) -IGLJ1*01 (91.7%), CDR-IMGT [9.3.12] (26-34.52-54.91-102)) (1'-112') -*Homo sapiens* IGLC2*01 (100%) (113'-218')]; dimer (233-233'':236-236'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa (Source: WHO pINN list 125)

STRUCTURAL FORMULA

Heavy chain X, X’’

EVQLVESGGG	LVKPGGSLRL	SCAASGFTFS	SYYMNWVRQA	PGKGLEWVSS	50
ISEDGYSTYY	PDSLKGRFTI	SRDSAKNSLY	LQMNSLRADD	TAVYYCARDF	100
SGHTAWAGTG	FEYWGQGTLV	TVSSASTKGP	SVFPLAPSSK	STSGGTAALG	150
CLVKDYFPEP	VTVSWNSGAL	TSGVHTFPAV	LQSSGLYSLS	SVVTVPSSSL	200
GTQTYICNVN	HKPSNTKVDK	RVEPKSCDKT	HTCPPCPAPE	LLGGPSVFLF	250
PPKPKDTLMI	SRTPEVTCVV	VDVSHEDPEV	KFNWYVDGVE	VHNAKTKPRE	300
EQYNSTYRVV	SVLTVLHQDW	LNGKEYKCKV	SNKALPAPIE	KTISKAKGQP	350
REPQVYTLPP	SREEMTKNQV	SLTCLVKGFY	PSDIAVEWES	NGQPENNYKT	400
TPPVLDSDGS	FFLYSKLTVD	KSRWQQGNVF	SCSVLHEALH	AHYTQKSLSL	450
SPGK					454

Light chain X’, X’’’

QSVLTQPPSV	SGAPGQRITI	SCTGSSSNIG	AGYDVHWYQQ	LPGTAPKLLI	50'
YGSSSRNSGV	PDRFSGSKSG	TSASLAITGL	QAEDEADYYC	QSYDSSLSVL	100'
YTFGTGTKVT	VLGQPKAAPS	VTLFPPSSEE	LQANKATLVC	LISDFYPGAV	150'
TVAWKADSSP	VKAGVETTTP	SKQSNNKYAA	SSYLSLTPEQ	WKSHRSYSCQ	200'
VTHEGSTVEK	TVAPTECS				218'

Disulfide bridges

22’-90’	22’’’-90’’’	22-96	22’’-96’’	140’-199’	140’’’-199’’’	151-207	151’’-207’’
217’-227	217’’’-227’’	233-233’’	236-236’’	268-328	268’’-328’’	374-432	374’’-432’’
		Or 233-236’’	236-233’’				

Glycosylation sites (N)

304	304’’

C-Terminal lysine clipping

454	454’’

MOLECULAR FORMULA	$C_{6428}H_{9932}N_{1700}O_{2032}S_{40}$
MOLECULAR WEIGHT	147.65 kDa (determined experimentally by firm)
TRADEMARK	None as yet
SPONSOR	Adagio Therapeutics, Inc.
CODE DESIGNATIONS	ADG20
CAS REGISTRY NUMBER	2516243-54-0
UNII	054Q5D7VZI
WHO NUMBER	12026

gbk